Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PROTAC: A promising technology for cancer treatment
Xin Zhou, Ru Dong, Jinyang Zhang, et al.
European Journal of Medicinal Chemistry (2020) Vol. 203, pp. 112539-112539
Closed Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications
Qian Zhong, Xina Xiao, Yijie Qiu, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 117
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
Skye Montoya, Jessie Bourcier, Mark Noviski, et al.
Science (2024) Vol. 383, Iss. 6682
Open Access | Times Cited: 68
PROTACs to address the challenges facing small molecule inhibitors
Pedro Martín-Acosta, Xiangshu Xiao
European Journal of Medicinal Chemistry (2020) Vol. 210, pp. 112993-112993
Open Access | Times Cited: 104
Developments of CRBN-based PROTACs as potential therapeutic agents
Chao Wang, Yujing Zhang, Yudong Wu, et al.
European Journal of Medicinal Chemistry (2021) Vol. 225, pp. 113749-113749
Closed Access | Times Cited: 96
Protein degradation technology: a strategic paradigm shift in drug discovery
Haobin Li, Jinyun Dong, Mao-Hua Cai, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 63
HDAC Inhibitors: Innovative Strategies for Their Design and Applications
Mateusz Daśko, Beatriz de Pascual‐Teresa, Irene Ortín, et al.
Molecules (2022) Vol. 27, Iss. 3, pp. 715-715
Open Access | Times Cited: 44
Ubiquitin–proteasome system as a target for anticancer treatment—an update
Yeon‐Jung Kim, Yeonjoo Lee, H. Y. Shin, et al.
Archives of Pharmacal Research (2023) Vol. 46, Iss. 7, pp. 573-597
Closed Access | Times Cited: 27
Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer
Zhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5351-5372
Closed Access | Times Cited: 12
Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019–2024)
Debasis Das, Lingzhi Xie, Hong Jian
RSC Medicinal Chemistry (2024)
Closed Access | Times Cited: 12
Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib
Fansheng Ran, Yun Liu, Chen Wang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 229, pp. 114009-114009
Closed Access | Times Cited: 52
Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective
Qiangsheng Zhu, Nannan Chen, Xinjian Tian, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 12, pp. 8065-8090
Closed Access | Times Cited: 34
Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: A review
Chao Wang, Yujing Zhang, Wujun Chen, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 4, pp. 188927-188927
Closed Access | Times Cited: 21
PROTACs: Promising approach for anticancer therapy
Simran Kaur, Neena Bedi, Deepak Kumar, et al.
Cancer Letters (2023) Vol. 556, pp. 216065-216065
Closed Access | Times Cited: 18
JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis
Junchao Wu, Lisha Li, Quangang Zhu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116167-116167
Open Access | Times Cited: 6
Discovery of a PROTAC targeting ALK with in vivo activity
Guoyi Yan, Xin-Xin Zhong, Yue Lin, et al.
European Journal of Medicinal Chemistry (2021) Vol. 212, pp. 113150-113150
Closed Access | Times Cited: 39
Targeting Protein Kinases Degradation by PROTACs
Fei Yu, Ming Cai, Liang Shao, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 38
Degrading FLT3-ITD protein by proteolysis targeting chimera (PROTAC)
Yong Chen, Xue Yuan, Minghai Tang, et al.
Bioorganic Chemistry (2021) Vol. 119, pp. 105508-105508
Closed Access | Times Cited: 34
MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment
André T. S. Vicente, Jorge A. R. Salvador
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11068-11068
Open Access | Times Cited: 26
Health horizons: Future trends and technologies from the European Medicines Agency’s horizon scanning collaborations
Valentina Vignali, Philip A. Hines, Ana Glória Cruz, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 19
Target protein degradation by protacs: A budding cancer treatment strategy
Diksha Choudhary, Amritpal Kaur, Pargat Singh, et al.
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108525-108525
Closed Access | Times Cited: 12
RNF112-mediated FOXM1 ubiquitination suppresses the proliferation and invasion of gastric cancer
Shengwei Zhang, Jing Wang, Weichao Hu, et al.
JCI Insight (2023) Vol. 8, Iss. 11
Open Access | Times Cited: 11
Identification and Development of BRD9 Chemical Probes
Ester Colarusso, Maria Giovanna Chini, Giuseppe Bifulco, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 392-392
Open Access | Times Cited: 4
Leukocyte immunoglobulin-like receptor B1 (LILRB1) protects human multiple myeloma cells from ferroptosis by maintaining cholesterol homeostasis
Miao Xian, Qiang Wang, Liuling Xiao, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
An updated review on the role of small molecule in mediating protein degradation
Zumei Wu, Yulong Li, Jinyun Dong, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117370-117370
Closed Access
Recent Advances in Medicinal Chemistry Strategies for the Development of METTL3 Inhibitors
G. Li, Wei Chen, Dan Liu, et al.
European Journal of Medicinal Chemistry (2025), pp. 117560-117560
Closed Access
Page 1 - Next Page

Scroll to top